MY163852A - Amidophenoxyindazoles useful as inhibitors of c-met. - Google Patents

Amidophenoxyindazoles useful as inhibitors of c-met.

Info

Publication number
MY163852A
MY163852A MYPI2011000343A MYPI2011000343A MY163852A MY 163852 A MY163852 A MY 163852A MY PI2011000343 A MYPI2011000343 A MY PI2011000343A MY PI2011000343 A MYPI2011000343 A MY PI2011000343A MY 163852 A MY163852 A MY 163852A
Authority
MY
Malaysia
Prior art keywords
useful
amidophenoxyindazoles
inhibitors
met
cancer
Prior art date
Application number
MYPI2011000343A
Other languages
English (en)
Inventor
Tiechao Li
Mark Andrew Póbanz
Chuan Shih
Zhipei Wu
Boyu Zhong
Wei Jennifer Yang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MY163852A publication Critical patent/MY163852A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
MYPI2011000343A 2008-07-24 2009-07-15 Amidophenoxyindazoles useful as inhibitors of c-met. MY163852A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8329408P 2008-07-24 2008-07-24
US8508208P 2008-07-31 2008-07-31
US10865908P 2008-10-27 2008-10-27

Publications (1)

Publication Number Publication Date
MY163852A true MY163852A (en) 2017-10-31

Family

ID=41010247

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011000343A MY163852A (en) 2008-07-24 2009-07-15 Amidophenoxyindazoles useful as inhibitors of c-met.

Country Status (36)

Country Link
US (2) US8030302B2 (US20070167479A1-20070719-C00034.png)
EP (1) EP2310382B1 (US20070167479A1-20070719-C00034.png)
JP (1) JP5414794B2 (US20070167479A1-20070719-C00034.png)
KR (1) KR101334456B1 (US20070167479A1-20070719-C00034.png)
CN (1) CN102105462B (US20070167479A1-20070719-C00034.png)
AR (1) AR074632A1 (US20070167479A1-20070719-C00034.png)
AT (1) ATE546444T1 (US20070167479A1-20070719-C00034.png)
AU (1) AU2009274256B2 (US20070167479A1-20070719-C00034.png)
BR (1) BRPI0916286B8 (US20070167479A1-20070719-C00034.png)
CA (1) CA2731773C (US20070167479A1-20070719-C00034.png)
CL (1) CL2011000134A1 (US20070167479A1-20070719-C00034.png)
CO (1) CO6351737A2 (US20070167479A1-20070719-C00034.png)
CR (1) CR20110046A (US20070167479A1-20070719-C00034.png)
CY (1) CY1112595T1 (US20070167479A1-20070719-C00034.png)
DK (1) DK2310382T3 (US20070167479A1-20070719-C00034.png)
DO (1) DOP2011000009A (US20070167479A1-20070719-C00034.png)
EA (1) EA018385B1 (US20070167479A1-20070719-C00034.png)
EC (1) ECSP11010778A (US20070167479A1-20070719-C00034.png)
ES (1) ES2379587T3 (US20070167479A1-20070719-C00034.png)
HK (1) HK1155172A1 (US20070167479A1-20070719-C00034.png)
HR (1) HRP20120202T1 (US20070167479A1-20070719-C00034.png)
IL (1) IL210490A (US20070167479A1-20070719-C00034.png)
JO (1) JO2788B1 (US20070167479A1-20070719-C00034.png)
MA (1) MA32594B1 (US20070167479A1-20070719-C00034.png)
MX (1) MX2011000925A (US20070167479A1-20070719-C00034.png)
MY (1) MY163852A (US20070167479A1-20070719-C00034.png)
NZ (1) NZ590013A (US20070167479A1-20070719-C00034.png)
PE (1) PE20110150A1 (US20070167479A1-20070719-C00034.png)
PL (1) PL2310382T3 (US20070167479A1-20070719-C00034.png)
PT (1) PT2310382E (US20070167479A1-20070719-C00034.png)
RS (1) RS52261B (US20070167479A1-20070719-C00034.png)
SI (1) SI2310382T1 (US20070167479A1-20070719-C00034.png)
SV (1) SV2011003816A (US20070167479A1-20070719-C00034.png)
TW (1) TWI365185B (US20070167479A1-20070719-C00034.png)
WO (1) WO2010011538A1 (US20070167479A1-20070719-C00034.png)
ZA (1) ZA201100219B (US20070167479A1-20070719-C00034.png)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045095A1 (en) 2008-10-14 2010-04-22 Ning Xi Compounds and methods of use
AU2010229147B2 (en) 2009-03-21 2012-07-05 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
RU2568258C2 (ru) 2011-02-28 2015-11-20 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования
JP5970003B2 (ja) * 2011-03-04 2016-08-17 ローカス ファーマシューティカルズ インコーポレイテッド アミノピラジン化合物
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
EP2870178B1 (en) * 2012-05-09 2017-07-12 Eli Lilly and Company Anti-c-met antibodies
EP2961744B1 (en) * 2013-02-27 2017-06-28 Array Biopharma, Inc. Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof
CN104140393B (zh) * 2013-12-10 2016-09-21 郑州泰基鸿诺医药股份有限公司 一种芳环/芳杂环叔丁醇酯类化合物的制备方法
JP6500037B2 (ja) 2014-04-22 2019-04-10 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーCalitor Sciences, Llc 二環式ピラゾロン化合物および使用方法
TW201716085A (zh) * 2015-08-12 2017-05-16 應克隆公司 癌症之組合療法
JP2019511541A (ja) 2016-04-15 2019-04-25 イーライ リリー アンド カンパニー 結腸直腸癌の処置における使用のためのラムシルマブとメレスチニブとの組み合わせ
CA3025894A1 (en) 2016-06-02 2017-12-07 Immunocore Limited Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
US20190269666A1 (en) * 2016-07-29 2019-09-05 Eli Lilly And Company Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
CN108069938A (zh) * 2016-11-15 2018-05-25 中国药科大学 2,4-二取代吡啶类化合物及其制备方法和应用
JP2019536771A (ja) 2016-11-16 2019-12-19 イーライ リリー アンド カンパニー エクソン14スキッピング変異またはエクソン14スキッピング表現型を有する癌の治療
EP3541383B1 (en) 2016-11-16 2021-01-06 Eli Lilly and Company Combination therapy for cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
CN107311983A (zh) * 2017-07-06 2017-11-03 北京万全德众医药生物技术有限公司 吲哚类小分子c‑met抑制剂
CN107382968A (zh) * 2017-07-06 2017-11-24 北京万全德众医药生物技术有限公司 一种吲哚类c‑Met抑制剂的制备方法
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
EP3480201A1 (en) 2017-11-06 2019-05-08 Oncostellae, S.L. New analogs as androgen receptor and glucocorticoid receptor modulators
EP3719012B1 (en) 2017-11-24 2024-03-06 Medshine Discovery Inc. N-[4-[(2-amino-4-pyridinyl)oxy]-3-fluorophenyl]-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinecarboxamide derivatives as c-met/axl inhibitors for the treatment of tumors
JP7282397B2 (ja) * 2018-01-17 2023-05-29 薬捷安康(南京)科技股▲分▼有限公司 Tamファミリーキナーゼ/及びcsf1rキナーゼ阻害剤及びその用途
EP3762392B1 (en) 2018-03-08 2024-05-15 Wellmarker Bio Co., Ltd. Thienopyridine derivatives and pharmaceutical composition comprising same
BR112021003447A2 (pt) * 2018-08-24 2021-05-18 Nanjing Transthera Biosciences Co., Ltd. inibidor derivado de quinolina inovador
JP7443373B2 (ja) 2018-09-03 2024-03-05 タイリガンド バイオサイエンス(シャンハイ)リミテッド 抗がん性薬物としてのtrk阻害剤
KR20220059386A (ko) 2019-09-06 2022-05-10 웰마커바이오 주식회사 바이오마커 기반 치료용 조성물
CN117355533A (zh) * 2021-06-22 2024-01-05 株式会社Lg化学 作为蛋白激酶抑制剂的新型化合物
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155316C (no) * 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US5484681A (en) * 1994-10-31 1996-01-16 Xerox Corporation Conductive composite particles and processes for the preparation thereof
IL114149A0 (en) * 1995-06-14 1995-10-31 Yeda Res & Dev Modified avidin and streptavidin molecules and use thereof
US5747577A (en) * 1995-12-27 1998-05-05 Xerox Corporation Conductive particles containing carbon black and processes for the preparation thereof
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
US6964872B2 (en) * 2001-05-18 2005-11-15 Srl, Inc. Immunoassay method
US6956084B2 (en) * 2001-10-04 2005-10-18 Bridgestone Corporation Nano-particle preparation and applications
JP2004067703A (ja) * 2002-04-24 2004-03-04 Japan Science & Technology Corp 架橋ポリマー、微粒子および製造方法
US7192780B2 (en) * 2002-10-23 2007-03-20 Evident Technologies Fluorescent lifetime biological detection and imaging using water-stable semiconductor nanocrystals
WO2004039796A1 (de) 2002-10-28 2004-05-13 Bayer Healthcare Ag Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
JP5344511B2 (ja) * 2003-07-17 2013-11-20 ライフ テクノロジーズ エーエス 被覆磁性粒子の調製方法
US7163998B2 (en) * 2003-09-09 2007-01-16 Eastman Kodak Company Stabilized polymer beads and method of preparation
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
KR101412675B1 (ko) 2005-12-21 2014-07-03 얀센 파마슈티카 엔.브이. 티로신 키나제 모듈레이터로서의 트리아졸로피리다진
EP2001880A2 (en) * 2006-03-07 2008-12-17 Array Biopharma, Inc. Heterobicyclic pyrazole compounds and methods of use
EP2038320B1 (en) * 2006-06-29 2014-03-12 Life Technologies AS Particles containing multi- block polymers
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
DK2084162T3 (da) 2006-10-23 2012-10-01 Sgx Pharmaceuticals Inc Bicykliske triazoler som proteinkinasemodulatorer
US8076521B2 (en) 2007-06-27 2011-12-13 Arkema Inc. Process for the manufacture of hydrofluoroolefins

Also Published As

Publication number Publication date
CL2011000134A1 (es) 2011-07-08
DK2310382T3 (da) 2012-03-26
AU2009274256A1 (en) 2010-01-28
ATE546444T1 (de) 2012-03-15
IL210490A0 (en) 2011-03-31
IL210490A (en) 2013-06-27
MA32594B1 (fr) 2011-09-01
ES2379587T3 (es) 2012-04-27
SI2310382T1 (sl) 2012-04-30
BRPI0916286B1 (pt) 2019-10-08
EA018385B1 (ru) 2013-07-30
EP2310382B1 (en) 2012-02-22
AR074632A1 (es) 2011-02-02
HRP20120202T1 (hr) 2012-03-31
CN102105462B (zh) 2014-07-23
EP2310382A1 (en) 2011-04-20
USRE43878E1 (en) 2012-12-25
TW201006817A (en) 2010-02-16
KR20110022691A (ko) 2011-03-07
US8030302B2 (en) 2011-10-04
KR101334456B1 (ko) 2013-11-29
JP5414794B2 (ja) 2014-02-12
PL2310382T3 (pl) 2012-07-31
CA2731773C (en) 2013-03-12
CN102105462A (zh) 2011-06-22
PT2310382E (pt) 2012-04-11
ECSP11010778A (es) 2011-02-28
DOP2011000009A (es) 2011-03-31
MX2011000925A (es) 2011-03-21
CY1112595T1 (el) 2016-02-10
CR20110046A (es) 2011-04-27
NZ590013A (en) 2012-06-29
AU2009274256B2 (en) 2013-07-11
PE20110150A1 (es) 2011-03-07
TWI365185B (en) 2012-06-01
JP2011529054A (ja) 2011-12-01
SV2011003816A (es) 2011-03-17
US20100022529A1 (en) 2010-01-28
CO6351737A2 (es) 2011-12-20
HK1155172A1 (en) 2012-05-11
RS52261B (en) 2012-10-31
BRPI0916286B8 (pt) 2021-05-25
WO2010011538A1 (en) 2010-01-28
CA2731773A1 (en) 2010-01-28
ZA201100219B (en) 2012-06-27
EA201170252A1 (ru) 2011-06-30
JO2788B1 (en) 2014-03-15

Similar Documents

Publication Publication Date Title
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
EA201171367A1 (ru) Винилиндазолильные соединения
IN2012DN03883A (US20070167479A1-20070719-C00034.png)
IN2012DN00471A (US20070167479A1-20070719-C00034.png)
PL2303021T3 (pl) Związki do leczenia nowotworu
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EP2569434A4 (en) COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA
EA201170832A1 (ru) Пуриновые соединения
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2009012228A (es) Compuesto de triazolil aminopirimidina.
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
EA200901074A1 (ru) Лечение метастатической стадии рака предстательной железы дегареликсом
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
EP2331520A4 (en) ROSAMINE DERIVATIVES AS AGENTS FOR CANCER TREATMENT
MX2013007268A (es) Activadores de pkm2 bicíclicos.
MY150600A (en) Use of opioid antagonists for treating urinary retention
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
MX2011006532A (es) Compuestos anticancerigenos.
AP2011005893A0 (en) Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer.
TN2011000013A1 (en) Amidophenoxyindazoles useful as inhibitors of c-met
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer
CY1114071T1 (el) Ενωσεις βινυλοϊνδαζολυλιου
UA36194U (en) Use of quercetin as hepatoprotector